Semaglutide treatment for type 2 diabetes in a patient with chronic myeloid leukemia: A case report and review of the literature.

IF 1.7 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Open Medicine Pub Date : 2025-04-23 eCollection Date: 2025-01-01 DOI:10.1515/med-2025-1184

Yuchen Zhang, Anxin Li

{"title":"Semaglutide treatment for type 2 diabetes in a patient with chronic myeloid leukemia: A case report and review of the literature.","authors":"Yuchen Zhang, Anxin Li","doi":"10.1515/med-2025-1184","DOIUrl":null,"url":null,"abstract":"Background: Comorbid type 2 diabetes mellitus (T2DM), severe obesity, and chronic myeloid leukemia (CML) present therapeutic challenges, especially given the limited data on glucagon-like peptide-1 (GLP-1) receptor agonists in this setting.Methods: We describe a 33-year-old female with poorly controlled T2DM (HbA1c 10.7%), severe obesity (BMI 47.05 kg/m2), and stable CML on tyrosine kinase inhibitor therapy. She received once-weekly semaglutide (0.5-1.5 mg) for 6 months, alongside insulin glargine and dapagliflozin/metformin. Clinical, biochemical, and molecular parameters were monitored.Results: After 6 months, her HbA1c declined from 10.7 to 5.5%, fasting plasma glucose from 16.2 to 5.3 mmol/L, and body weight decreased by 18 kg. Lipid parameters improved, and molecular analysis confirmed continued CML remission (undetectable BCR-ABL1). The patient experienced only mild, transient gastrointestinal side effects.Conclusion: In this complex case, semaglutide proved safe and effective for achieving glycemic control and weight reduction without compromising CML stability. These findings suggest that GLP-1 receptor agonists may be a viable therapeutic option for patients with coexisting T2DM, severe obesity, and stable CML, warranting further investigation in broader populations.","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"20 1","pages":"20251184"},"PeriodicalIF":1.7000,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12032985/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/med-2025-1184","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Comorbid type 2 diabetes mellitus (T2DM), severe obesity, and chronic myeloid leukemia (CML) present therapeutic challenges, especially given the limited data on glucagon-like peptide-1 (GLP-1) receptor agonists in this setting.

Methods: We describe a 33-year-old female with poorly controlled T2DM (HbA1c 10.7%), severe obesity (BMI 47.05 kg/m²), and stable CML on tyrosine kinase inhibitor therapy. She received once-weekly semaglutide (0.5-1.5 mg) for 6 months, alongside insulin glargine and dapagliflozin/metformin. Clinical, biochemical, and molecular parameters were monitored.

Results: After 6 months, her HbA1c declined from 10.7 to 5.5%, fasting plasma glucose from 16.2 to 5.3 mmol/L, and body weight decreased by 18 kg. Lipid parameters improved, and molecular analysis confirmed continued CML remission (undetectable BCR-ABL1). The patient experienced only mild, transient gastrointestinal side effects.

Conclusion: In this complex case, semaglutide proved safe and effective for achieving glycemic control and weight reduction without compromising CML stability. These findings suggest that GLP-1 receptor agonists may be a viable therapeutic option for patients with coexisting T2DM, severe obesity, and stable CML, warranting further investigation in broader populations.

查看原文本刊更多论文

西马鲁肽治疗2型糖尿病合并慢性髓性白血病1例：1例报告及文献复习。

背景：合并症2型糖尿病（T2DM）、严重肥胖和慢性髓性白血病（CML）的治疗面临挑战，特别是考虑到在这种情况下胰高血糖素样肽-1 （GLP-1）受体激动剂的数据有限。方法：我们描述了一名33岁的女性，患有控制不良的T2DM (HbA1c 10.7%)，严重肥胖（BMI 47.05 kg/m2），酪氨酸激酶抑制剂治疗后稳定的CML。她每周接受一次semaglutide （0.5-1.5 mg）治疗6个月，同时接受甘精胰岛素和达格列净/二甲双胍治疗。监测临床、生化和分子参数。结果：6个月后，患者HbA1c由10.7降至5.5%，空腹血糖由16.2降至5.3 mmol/L，体重下降18 kg。脂质参数改善，分子分析证实CML持续缓解（未检测到BCR-ABL1）。患者只有轻微的、短暂的胃肠道副作用。结论：在这个复杂的病例中，西马鲁肽被证明是安全有效的，可以实现血糖控制和体重减轻，而不会影响CML的稳定性。这些发现表明，GLP-1受体激动剂可能是T2DM、重度肥胖和稳定型CML患者的可行治疗选择，值得在更广泛的人群中进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open Medicine Medicine-General Medicine

CiteScore

3.00

自引率

0.00%

发文量

153

审稿时长

20 weeks

期刊介绍： Open Medicine is an open access journal that provides users with free, instant, and continued access to all content worldwide. The primary goal of the journal has always been a focus on maintaining the high quality of its published content. Its mission is to facilitate the exchange of ideas between medical science researchers from different countries. Papers connected to all fields of medicine and public health are welcomed. Open Medicine accepts submissions of research articles, reviews, case reports, letters to editor and book reviews.